A carregar...
Relationship between molecular response and quality of life with bosutinib or imatinib for chronic myeloid leukemia
Patients with newly diagnosed chronic phase chronic myeloid leukemia (CP CML) can be effectively treated with tyrosine kinase inhibitors (TKIs) and achieve a lifespan similar to the general population. The success of TKIs, however, requires long-term and sometimes lifelong treatment; thus, patient-a...
Na minha lista:
| Publicado no: | Ann Hematol |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer Berlin Heidelberg
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7237399/ https://ncbi.nlm.nih.gov/pubmed/32307568 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00277-020-04018-1 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|